Skip to main content
. 2012 Sep 17;28(1):137–146. doi: 10.1093/ndt/gfs379

Fig. 4.

Fig. 4.

Percentage of reduction of UPs and on anti-PLA2R antibody levels over time in patient who responded to RTX therapy. % reduction = [(UP baseline – UP 3, 6, 9, 12 months)/UP baseline] × 100.

HHS Vulnerability Disclosure